University of Erlangen-Nürnberg Medical School

• NCT06560801

  Phase 4, Recruiting, 48 people, 19 Aug 2024

• NCT06244758

  Phase 3, Completed, 91 people, 6 Feb 2024

• NCT04610476

  Phase 3, Status unknown, 270 people, 30 Oct 2020

• NCT03701789

  Phase 3, Status unknown, 15 people, 10 Oct 2018

• NCT03128528

  Phase 2, Completed, 84 people, 25 Apr 2017

• NCT02752113

  Collaborator, Phase 3, Completed, 101 people, 26 Apr 2016

• NCT02483221

  Phase 4, Completed, 50 people, 26 Jun 2015

• Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

  Phase 3, Completed, 74 people, 15 Jun 2015

• Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content

  Phase 3, Completed, 59 people, 9 Mar 2015

• NCT02369939

  Phase 3, Status unknown, 118 people, 24 Feb 2015

• NCT01827553

  Phase 3, Completed, 830 people, 9 Apr 2013

• NCT01716949

  Phase 1/2, Status unknown, 59 people, 30 Oct 2012

• NCT01126216

  Phase 3, Terminated, 221 people, 19 May 2010

• NCT00865501

  Phase 3, Completed, 50 people, 19 Mar 2009

• NCT00823290

  Phase 1, Terminated, 2 people, 15 Jan 2009

• NCT00488124

  Phase 2, Completed, 120 people, 19 Jun 2007

• NCT00349076

  Phase 3, Completed, 1,256 people, 6 Jul 2006

• NCT00328393

  Phase 3, Completed, 2 people, 19 May 2006

• NCT00160745

  Phase 2, Completed, 46 people, 12 Sept 2005

• NCT00152633

  Phase 2/3, Withdrawn, 0 people, 9 Sept 2005

Sources: clinicaltrials.gov